[1] 魏农农, 王霞, 苏敏. 药物溶出度试验方法研究进展[J].中国新药杂志, 2013,(10):1119
WEI NN, WANG X, SU M. Progress of dissolution test methodologies[J].Chin J New Drugs, 2013, (10):1119
[2] SHOHIN IE, GREBENKIN DY, MALASHENKO EA, et al. A brief review of the FDA dissolution methods database[J].Dissol Technol, 2016, 23(3):6
[3] 许鸣镝, 胡琴. 中,美,英三国新版药典溶出度、释放度检查方法比较[J].中国药学杂志, 2000, 35(7):491
XU MD, HU Q. Comparison of dissolution and release test methods of new Chinese, American and British Pharmacopoeia[J].Chin Pharm J, 2000, 35(7):491
[4] ZAFFARONI A. ALZA: an enterprise in biomedical innovation[J].Technovation, 1981, 1(2):135
[5] THAKKER K. Topicals and Transdermals[M].Durham NC: John Wiley & Sons Ltd.2020:155
[6] 由春娜,宋宗华,张启明,等.透皮贴剂仿制药研发和监管考量[J].中国新药杂志,2020,29(24):2801
YOU CN, SONG ZH, ZHANG QM, et al. R&D of generic transdermal patches and regulatory considerations [J].Chin J New Drugs,2020,29(24):2801
[7] ZAFFARONI A.Bandage for Administratering Drugs:US, 3598122[P].1971-08-10
[8] GERSTEL M, PLACE VA. Drug Delivery Device: US, 3964482 [P].1976-06-22
[9] USP XXII-NF XVII [S].1990:1580
[10] USP 23-NF 18 Supplement 2 [S].1995:2709
[11] ROSE S, NELSON J. A continuous long-term injector[J].Immunol Cell Biol, 1955, 33(4):415
[12] HIGUCHI T, THEEUWES F. Osmatic Dispensing Device For Releasing Beneficial Agent[P].1972-06-05
[13] THEEUWES F. Elementary osmotic pump[J].J Pharm Sci, 1975, 64(12):1987
[14] 杨庭树,韩宝石. 药物洗脱支架[J].解放军保健医学杂志,2004,6(3):183
YANG TS, HAN BS.Drug-eluting sent[J].Chin J Health Care Med, 2004,6(3):183
[15] Dissolution Technologies. Industry News[EB/OL]. (2007-05) [2022-07-10]. http://dissolutiontech.com/DTresour/200705Articles/inews.html
[16] WILEY A. Center for Drug Evaluation and Research Application Number 22-315[R/OL]. (2009-06-17) [2022-07-10]. https://www.accessdata.fda.gov/drugsatfda_docs/hda/2009/022315s000_sumr.pdf
[17] 国家药典委员会. 2021年度国家药品标准提高课题目录公示[EB/OL]. (2021-03-31) [2022-07-10]. https://www.chp.org.cn/gjydw/tz/15929.jhtml
Chinese Pharmacopoeia Commission. 2021 National drug standards improvement project published list[EB/OL]. (2021-03-31) [2022-07-10]. https://www.chp.org.cn/gjydw/tz/15929.jhtml
[18] MAZZO DJ, FONG EKF,BIFFAR SE. A comparison of test methods for determining in vitro drug release from transdermal delivery dosage forms[J].J Pharm Biomed Anal,1986,4(5):601
[19] ZHOU MX, SHOUDT D, CALDERON G, et al. Application of USP apparatus 7 to in vitro drug release in Scopolamine Transdermal Systems[J].Dissolution Technol, 2007, 14(2):25
[20] USP 43-NF 38[S].2020:1105,3153,3163,3329,4461,2892,972
[21] STEIN S, AUEL T, KEMPIN W, et al. Influence of the test method on in vitro drug release from intravitreal model implants containing dexamethasone or fluorescein sodium in poly (D,L-lactide-co-glycolide) or polycaprolactone [J].Eur J Pharm Biopharm, 2018, 127: 270
[22] EXTERNBRINK A, EGGENREICH K, EDER S, et al. Development and evaluation of accelerated drug release testing methods for a matrix-type intravaginal ring[J].Eur J Pharm Biopharm, 2017, 110: 1
[23] JØRGENSEN J R, THAMDRUP L, KAMGUYAN K, et al. Design of a self-unfolding delivery concept for oral administration of macromolecules [J].J Controll Release, 2020, 329:948
[24] SEIDLITZ A, SCHICK W, RESKE T, et al. In vitro study of sirolimus release from a drug-eluting stent: Comparison of the release profiles obtained using different test setups[J].Eur J Pharm Biopharm, 2015, 93:328
[25] SEIDLITZ A, NAGEL S, SEMMLING B, et al. In vitro dissolution testing of drug-eluting stents[J].Curr Pharm Biotechnol, 2013, 14(1):67
[26] LI M, TAN H. Technical note: comparison of USP apparatus 5 and 7 for in vitro drug release from nicotine transdermal systems[J].Dissolut Technol, 2019, 26(3):68
[27] CRIST GB. 2009 Trends in small-volume dissolution apparatus for low-dose compounds[J].Dissolut Technol, 2009, 16(1):19
[28] AZARMI S, ROA W, LÖBENBERG R. Current perspectives in dissolution testing of conventional and novel dosage forms[J].International J Pharm, 2007, 328(1):12
[29] MA K, JIANG W, WANG YX, et al. Expert consensus of the Chinese Association for the Study of Pain on pain treatment with the transdermal patch[J].World J Clin Cases, 2021, 9(9):13
[30] 程雪翔. 可乐定透皮贴剂的研究进展与降压效果临床评价[J].中国医院用药评价与分析, 2007,7(2):99
CHEN XX. Advancement in the study of Clonidine transdermal patch and evaluation of its clinical antihypertensive efficacy[J].Eval Anal Drug Use Hosp China, 2007, 7(2):99
[31] MIN X, LIEW CV, HENG P. Evaluation of the coat quality of sustained release pellets by individual pellet dissolution methodology[J].Int J Pharm, 2014, 478(1):318
[32] 徐光奇, 吴金虎. 尼古丁透皮贴片和戒烟作用[J].中国药学杂志, 1997, 32(5):268
XU GQ, WU JH.Nicotine transdermal patch and smoking cessation [J].Chin Pharm J, 1997, 32(5):268
[33] 张鸣. 控释微丸技术在化学药物制备工艺中的应用[J].化工管理, 2021(36):80
ZHANG M. Application of controlled release pellet technology in the preparation of chemical drug preparation[J].Chem Enterprise Managt, 2021(36):80
[34] SILVA GR, FIALHO SL, SIQUEIRA RC, et al. Implants as drug delivery devices for the treatment of eye diseases[J].Brazilian J Pharm Sci, 2010, 46(3):585
[35] FIALHO S L, BEHAR-COHEN F, SILVA-CUNHA A, et al. Dexamethasone-loaded poly (ε-caprolactone) intravitreal implants: a pilot study[J].Eur J Pharm Biopharm, 2008, 68(3):63
[36] MATTER B, GHAFFARI A, BOURNE D, et al. Dexamethasone degradation in aqueous medium and implications for correction of in vitro release from sustained release delivery systems[J].AAPS PharmSciTech, 2019, 20(8):1
[37] 陈燕娜,栾瀚森,王浩.甘露醇对地塞米松PLGA植入剂体外释放行为的影响[J].中国医药工业杂志,2017,48(8):1148
CHEN YN, LUAN HS, WANG H. Effect of mannitol on in vitro release behavior of dexamethasone PLGA implant [J].Chin J Pharm,2017, 48(8):1148
[38] ENGÜLA, ARTUNA Y, KUMRAL ET, et al. Dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion: 6 months results[J].Retina Vitreus, 2015, 23(3):219
[39] EXTERNBRINK A. Investigating the Feasibility of Accelerated Drug Release Testing for Intravaginal Rings[D].Greifswald, Germany: Ernst Moritz Arndt University of Greifswald, 2014
[40] 张靓, 李德爽, 谷浩,等. 玻璃体病理生理学及玻璃体替代物研究进展[J].世界最新医学信息文摘, 2020, 20(60):87
ZHANG L, LI DS, GU H, et al. Progress in vitreous pathophysiology and vitreous substitutes[J].World Latest Med Inf, 2020, 20(60):87
[41] AUEL T, GROßMANN L, SCHULIG L, et al. the eyeflowcell: development of a 3D-printed dissolution test setup for intravitreal dosage forms[J].Pharmaceutics, 2021, 13(9):1394
[42] TIETZ K, KLEIN S. In vitro methods for evaluating drug release of vaginal ring formulations-a critical review[J].Pharmaceutics, 2019, 11(10):538
[43] HUSSAIN A, AHSAN F. The vagina as a route for systemic drug delivery [J].J Controll Release, 2005, 103(2):301
[44] 段雪艳, 陈凯, 王介东,等. 阴道环研究进展[C]// 第三届全国妇产科药学大会论文集. 北京:中国药学会, 2011
DUAN XY, CHEN K, WANG JD, et al. Advances in vaginal ring research [C]// Proceedings of the 3rd National Congress of Obstetrics and Gynecology. Beijing: Chinese Pharmaceutical Association, 2011
[45] DUNCAN G W. Medicated devices and methods: US, US3545439 A[P].1970-12-08
[46] EXTERNBRINK A, CLARK MR, FRIEND DR, et al. Investigating the feasibility of temperature-controlled accelerated drug release testing for an intravaginal ring[J].Euro J Pharm Biopharma, 2013, 85(3):966
[47] 陈文平,詹红兵.药物洗脱支架载药涂层研究进展[J].药学学报,2011,46(11):1301
CHEN WP, ZHAN HB. Recent developments of drug eluting stent coatings[J].Acta Pharm Sin,2011,46(11):1301
[48] NEUBERT A, STERNBERG K, NAGEL S, et al. Development of a vessel-simulating flow-through cell method for the in vitro evaluation of release and distribution from drug-eluting stents[J].J Controll Release, 2008, 130(1):2
[49] PRUESSMANN K, WENTZLAFF M, SCHILLING R, et al. Influence of dissolution vessel geometry and dissolution medium on in vitro dissolution behaviour of triamterene-coated model stents in different test setups[J].AAPS PharmSciTech, 2019, 20(1):1
